Trial Profile
A Phase II, Single-Arm Open-Label Study Of The Combination Of Atezolizumab And Bevacizumab In Rare Solid Tumors
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 16 Oct 2023
Price :
$35
*
At a glance
- Drugs Atezolizumab (Primary) ; Bevacizumab
- Indications Adenocarcinoma; Anal cancer; Appendiceal cancer; Carcinoma; Cervical cancer; Malignant-mesothelioma; Merkel cell carcinoma; Nasopharyngeal cancer; Neuroendocrine tumours; Pancreatic cancer; Penile cancer; Peritoneal cancer; Solid tumours; Squamous cell cancer; Vulvovaginal cancer
- Focus Therapeutic Use
- 12 Oct 2023 Planned End Date changed from 1 Dec 2023 to 30 Jun 2024.
- 12 Oct 2023 Planned primary completion date changed from 1 Dec 2023 to 30 Jun 2024.
- 01 Jul 2023 Results (n=20) assessing Biomarkers associated with survival benefit to atezolizumab and bevacizumab for treatment of metastatic anal cancer presented at the 25th World Congress on Gastrointestinal Cancer